Position
Rangeley Capital, LLC in Arbutus Biopharma Corp
Back to the book · All holders of ABUS
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$155K$4.81 → $4.50
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 840K | $4.04M | — | — | — | 3.4% |
| Q1 2026 | 500K | $2.25M | $4.50 | −$155K | −$1.64M | 2.2% |